MeSH D014549 - urinary incontinence
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Teva | Oxybutynin | Kentera (previously Oxybutynin Nicobrand) | 2004-06-15 | |||
| Oxybutynin | Oxybutynin | 1988-11-14 | ||||
| Tolterodine | Tolterodine | 2015-02-23 | ||||
| Novast Laboratories | Oxybutynin | Oxybutynin | 2019-10-30 | |||
| Mylan | Oxybutynin | Oxybutynin | 2006-11-09 | |||
| Tolterodine | Tolterodine | 2012-11-27 | ||||
| Johnson & Johnson | Oxybutynin | Ditropan | 1982-01-01 | |||
| Allergan | Oxybutynin | Gelnique | 2022-06-25 | 2011-12-07 | ||
| Oxybutynin | Oxytrol | 2003-02-26 | ||||
| Oxybutynin | Oxybutynin | 1989-04-19 |
1
2
3
4
5
6
>
Clinical Trials
Historical Success Rate
Phase 1
100%4/4
Phase 2
70%7/10
Phase 3
71%12/17
Approved: 6Overall Success rate: 49%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
1
2
3
4
>
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use